44 results on '"De Sèze, Jerome"'
Search Results
2. Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
3. Correction: Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
4. The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus
5. Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: A real-life observational study
6. Disease modifying therapies and disease activity during pregnancy and postpartum in a contemporary cohort of relapsing Multiple Sclerosis patients
7. Diagnosis and classification of optic neuritis
8. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar
9. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
10. COVID-19 exposure in SARS-CoV-2-seropositive hospital staff members during the first pandemic wave at Strasbourg University Hospital, France
11. Myelin-oligodendrocyte glycoprotein antibody-associated disease
12. Multiple sclerosis diagnostic criteria: From poser to the 2017 revised McDonald criteria
13. Evaluation of the performance of SARS-CoV-2 serological tools and their positioning in COVID-19 diagnostic strategies
14. Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement
15. Expert opinion: Criteria for second-line treatment failure in patients with multiple sclerosis
16. Emotional disturbances in multiple sclerosis: A neuropsychological and fMRI study
17. Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study★★
18. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD)
19. Multiple sclerosis with atypical MRI presentation: Results of a nationwide multicenter study in 57 consecutive cases
20. Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders
21. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial
22. Giving meaning to illness: An investigation of self-defining memories in patients with relapsing-remitting multiple sclerosis patients
23. Functional and structural cerebral changes in key brain regions after a facilitation programme for episodic future thought in relapsing-remitting multiple sclerosis patients
24. The biological sample collection of the OFSEP French MS registry: An essential tool dedicated to researchers
25. Characterization of a new rat model for chronic inflammatory demyelinating polyneuropathies
26. No evidence for genetic association between glutamate transporter EAAT2 and Devic's neuromyelitis optica in caucasians and afro-caribbeans
27. Longitudinal change detection: Inference on the diffusion tensor along white matter pathways
28. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
29. Review of animal models of neuromyelitis optica
30. Treatment of neuromyelitis optica: Review and recommendations
31. Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE
32. Longitudinal change detection in diffusion MRI using multivariate statistical testing on tensors
33. Efficacy and Safety of Satralizumab for Relapse Prevention in Neuromyelitis Optica Spectrum Disorder: A Pooled Analysis from Two Phase 3 Clinical Trials
34. Diversified serum IgG response involving non-myelin CNS proteins during experimental autoimmune encephalomyelitis
35. Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?
36. Radiologically isolated syndrome in children
37. Anti-pseudo-PCNA type 1 (anti-SG2NA) pattern: Track down Cancer, not SLE
38. Lyme optic neuritis
39. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.
40. Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.
41. Determination of interferon beta neutralizing antibodies in multiple sclerosis: Improvement of clinical sensitivity of a cytopathic effect assay
42. Characterization of the humoral immune response in a Lewis rat model of CIDP
43. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.
44. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.